Log in to search using one of your social media accounts:

 

2nd Atlas of Variation in risk factors and healthcare for liver disease published
This is intended for clinicians, commissioners, practitioners and policy makers, the atlas is intended to raise the profile of liver disease and the variations across England in risk factors, healthcare services and outcomes. The rate of people dying early from liver disease in some parts of England is almost eight times higher than others (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 18, 2017 Category: Consumer Health News Source Type: news

Rosetrees Trust Interdisciplinary Prize awarded to Hebrew University scientists
(The Hebrew University of Jerusalem) The Rosetrees Trust Interdisciplinary Prize for 2017 has been awarded to two scientists from the Hebrew University of Jerusalem, Prof. Yaakov Nahmias and Prof. Nir Friedman, for their research proposal to engineer a platform that mimics the physiological dynamics of human metabolism. The research will be instrumental to drug development, offering a route to the rational design of therapeutics for obesity, fatty liver disease and type 2 diabetes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2017 Category: International Medicine & Public Health Source Type: news

Updated Advice on Managing Liver Disease During Pregnancy Updated Advice on Managing Liver Disease During Pregnancy
Dr Rowen Zetterman reviews the new American College of Gastroenterology guidelines on caring for pregnant patients with diseases ranging from liver masses to viral infections.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Gastroenterology Expert Column Source Type: news

UofL gastroenterology researcher receives $4 million for innovative liver research
(University of Louisville) UofL gastroenterologist Matthew Cave, M.D., believes that chemicals we breathe, consume or come in contact with in the environment may be contributing to liver disease in as many as one in four people. He has been awarded a RIVER grant of $4.01 million over eight years by the National Institute of Environmental Health Sciences, one of the National Institutes of Health, to explore the long-term effects of environmental chemicals on the liver. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 15, 2017 Category: International Medicine & Public Health Source Type: news

Liver disease warning: More people are dying from condition in THIS area of the country
LIVER disease kills thousands of people each year but the death rate varies greatly across England, with eight times the number dying in Blackpool than South Norfolk. (Source: Daily Express - Health)
Source: Daily Express - Health - September 14, 2017 Category: Consumer Health News Source Type: news

Blackpool residents are more at risk of liver disease
Some 30.1 per 100,000 people from the north-west seaside town die from the condition before the age of 75. This is compared to just 3.9 per 100,000 in south Norfolk, according to Public Health England. (Source: the Mail online | Health)
Source: the Mail online | Health - September 14, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Do you have diabetes, liver disease? Watch out for CVD
A new study shows that non-alcoholic fatty liver disease puts people with type 2 diabetes at a much higher risk of cardiovascular disease and death. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 13, 2017 Category: Consumer Health News Tags: Diabetes Source Type: news

How liver cancer develops
(University of Zurich) Researchers at the University of Zurich and the University Hospital Zurich have discovered a major mechanism in the development of liver cancer. In chronic liver diseases, damaged cells die off and are replaced by new ones over a period of years. As time goes on, DNA damage accumulates, furthering the development of cancer. The caspase-8 enzyme plays an important dual role in this process. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

Trigger for fatty liver in obesity
(University of Zurich) Morbid obesity affects the liver: almost one-third of all adults suffer from chronic fatty liver disease, which can lead to infections and even trigger cancer. Researchers at the University Children's Hospital Zurich and the University of Zurich have now found a signaling pathway in cells that play an important role in the development of fatty liver disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2017 Category: Cancer & Oncology Source Type: news

Heart Benefit of Alcohol Not Seen in NAFLD Heart Benefit of Alcohol Not Seen in NAFLD
Light to moderate drinkers may have a lower risk of heart disease than teetotalers, but a new study suggests this doesn't hold true in non-alcoholic fatty liver disease (NAFLD).Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 7, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Heart benefit of alcohol not seen in people with liver disease
(Reuters Health) - Light to moderate drinkers may have a lower risk of heart disease than teetotalers, but a new study suggests this doesn ’t hold true for people with fatty liver disease. (Source: Reuters: Health)
Source: Reuters: Health - September 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

San Diego County declares emergency amid hepatitis outbreak
Officials in San Diego County have declared a public health emergency due to the spread of the liver disease hepatitis A (Source: ABC News: Health)
Source: ABC News: Health - September 2, 2017 Category: Consumer Health News Tags: Health Source Type: news

Nonalcoholic Fatty Liver Disease Epidemic Increasing Greatly Nonalcoholic Fatty Liver Disease Epidemic Increasing Greatly
The burden of nonalcoholic fatty liver disease (NAFLD) is increasing greatly, and the need for liver transplants is likely to outstrip the supply of donors, researchers report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - August 31, 2017 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news

Your NEJM Group Today: Diagnosing Liver Disease / Lung Cancer Increasing in Nonsmokers / Ohio Hospitalist Opportunities (FREE)
By the Editors Have a look at today's selections from NEJM Group:NEJM Clinical Practice Center: Review article: Advances in imaging techniques … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 28, 2017 Category: Primary Care Source Type: news

Enzyme produced in the liver promotes obesity, fatty liver disease and insulin resistance
In mice given a high fat diet, an increased production of the enzyme DPP4 by the liver promotes an increase in body fat, the development of fatty liver disease and insulin resistance. According to the study, published in Molecular Metabolism, DPP4 production is therefore a cause rather than result of fatty liver and insulin resistance.Science Daily  (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 25, 2017 Category: Endocrinology Source Type: news

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3)(1), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH. (Source: World Pharma News)
Source: World Pharma News - August 25, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Heart hormones protect against obesity and insulin resistance
(Sanford-Burnham Prebys Medical Discovery Institute) By fleshing out how one signaling receptor contributes to causing obesity through its activity in fatty tissue but not in muscle cells, SBP scientists have zeroed in on an important new avenue of exploration for combating metabolic disease. More than one-third of American adults are considered to be obese, which dramatically increases their risk for developing type 2 diabetes, non-alcoholic fatty liver disease, high blood pressure, and multiple inflammatory conditions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 25, 2017 Category: International Medicine & Public Health Source Type: news

Enzyme produced in the liver promotes obesity, fatty liver disease and insulin resistance
(Deutsches Zentrum fuer Diabetesforschung DZD) In mice that are given a high-fat diet, an increased production of the enzyme DPP4* by the liver promotes an increase in body fat, the development of fatty liver disease and insulin resistance. These were the findings of a current study by DZD-researchers in Potsdam and T ü bingen. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 24, 2017 Category: International Medicine & Public Health Source Type: news

Fatty liver can cause damage to other organs
NAFLD increases the risk of chronic liver disease, type 2 diabetes and cardiovascular diseases by releasing glucose, fats and proteins into the bloodstream, according to research published inScientific Reports. The secreted substances trigger reactions in other organs, causing further damage. Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 22, 2017 Category: Endocrinology Source Type: news

Your NEJM Group Today: Migraine Clinical Pearls / Alcohol Intake in Nonalcoholic Fatty Liver Disease / Okla. Primary Care Opportunity (FREE)
By the Editors Take a look at today's offering from NEJM Group:NEJM Resident 360: Clinical Pearls: Are … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 22, 2017 Category: Primary Care Source Type: news

Fatty liver disease: Complex condition can also damage other organs
NON-ALCOHOLIC fatty liver disease is a condition usually seen in people who are obese or overweight. (Source: Daily Express - Health)
Source: Daily Express - Health - August 21, 2017 Category: Consumer Health News Source Type: news

Research reveals potential target for alcohol liver disease
(Beth Israel Deaconess Medical Center) Drinking too much alcohol can damage the liver, but investigators have discovered a protective response in the organ that might be targeted to help treat alcoholic liver disease. The team -- led by researchers at Beth Israel Deaconess Medical Center, in collaboration with colleagues at the University of Pennsylvania -- also found that the same protective response may be involved in aversion to alcohol and could therefore help in the treatment of alcoholism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 21, 2017 Category: International Medicine & Public Health Source Type: news

Organ crosstalk: Fatty liver can cause damage to other organs
(Deutsches Zentrum fuer Diabetesforschung DZD) Scientists of the German Center for Diabetes Research (DZD) in T ü bingen discovered that a fatty liver can cause damage to other organs. In two just-published studies they demonstrate the effects of fatty liver disease on the function of the hormone-producing islet cells in the pancreas and on renal function. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2017 Category: International Medicine & Public Health Source Type: news

Alcohol warning: THIS trendy spice can protect you from liver disease caused by drinking
ALCOHOL consumed in large amounts is the main cause in the Western world of liver disease, which includes fatty liver, alcoholic hepatitis, and chronic hepatitis with liver fibrosis or cirrhosis. However, a popular spice may provide a beneficial effect if you ’ve overdone the drinking. (Source: Daily Express - Health)
Source: Daily Express - Health - August 15, 2017 Category: Consumer Health News Source Type: news

Cutting high fructose corn syrup from diet can reverse insulin resistance and high cholesterol
A study, published inThe Journal of the American Osteopathic Association suggests that removing fructose from the diet can combat obesity, fatty liver disease, diabetes and insulin resistance.Express (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 15, 2017 Category: Endocrinology Source Type: news

Medical News Today: How is hepatitis C transmitted?
In this article, learn about how hepatitis C is transmitted, the types of hepatitis, their symptoms, and how to prevent transmission of the virus. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 12, 2017 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

Urine colour warning: The shade of your wee could indicate THIS deadly condition
URINE colour can be used to diagnose a number of health problems, including liver disease, kidney disease and a urinary tract infection. (Source: Daily Express - Health)
Source: Daily Express - Health - August 11, 2017 Category: Consumer Health News Source Type: news

Ditching THIS sugar in fizzy drinks 'can combat obesity, fatty liver disease and diabetes'
DITCHING a type of sugar found in fizzy drinks and cakes can combat obesity, fatty liver disease and diabetes - and the results can be seen in just eight days. (Source: Daily Express - Health)
Source: Daily Express - Health - August 11, 2017 Category: Consumer Health News Source Type: news

Identifying a new type of liver tumor
(Children's Hospital Los Angeles) Investigators at Children's Hospital Los Angeles have succeeded in better defining a rare pediatric malignant liver disease -- a necessary step in achieving an optimum treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 9, 2017 Category: Cancer & Oncology Source Type: news

Liver disease and alcohol: Do YOU know what counts as drinking too much?
ALCOHOL-related liver disease refers to liver damage caused by excess alcohol intake. There are several stages of severity and a range of associated symptoms. (Source: Daily Express - Health)
Source: Daily Express - Health - August 8, 2017 Category: Consumer Health News Source Type: news

TRIF-dependent Toll-like receptor signaling suppresses Scd1 transcription in hepatocytes and prevents diet-induced hepatic steatosis
Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of diseases that ranges in severity from hepatic steatosis to steatohepatitis, the latter of which is a major predisposing factor for liver cirrhosis and cancer. Toll-like receptor (TLR) signaling, which is critical for innate immunity, is generally believed to aggravate disease progression by inducing inflammation. Unexpectedly, we found that deficiency in TIR domain–containing adaptor-inducing interferon-β (TRIF), a cytosolic adaptor that transduces some TLR signals, worsened hepatic steatosis induced by a high-fat diet (HFD) and that such exacerbati...
Source: Signal Transduction Knowledge Environment - August 8, 2017 Category: Science Authors: Chen, J., Li, J., Yiu, J. H. C., Lam, J. K. W., Wong, C.-M., Dorweiler, B., Xu, A., Woo, C. W. Tags: STKE Research Articles Source Type: news

Medical News Today: Ascites: Causes, symptoms, and treatment
Ascites is a symptom of liver disease, heart failure, and cancer. It involves uncomfortable abdominal swelling. The underlying causes can be fatal. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 5, 2017 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news

Reverse fatty liver disease: Drug could CURE condition caused by obesity
NON-alcoholic fatty liver disease is a condition usually seen in people who are obese or overweight, however now experts think there could be a cure. (Source: Daily Express - Health)
Source: Daily Express - Health - August 4, 2017 Category: Consumer Health News Source Type: news

FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C
August 3, 2017 -- The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 3, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves Mavyret for Hepatitis C
The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection who have been previously treated with a regimen either containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 3, 2017 Category: American Health Source Type: news

Of Mice and Cheeseburgers: Experimental Drug Reverses Obesity-Related Liver Disease
A drug developed at the University of Rochester Medical Center protected mice from one of the many ills of our cheeseburger and milkshake-laden Western diet – non-alcoholic fatty liver disease. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - August 3, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Of mice and cheeseburgers: Experimental drug reverses obesity-related liver disease
(University of Rochester Medical Center) An experimental drug protected mice from one of the many ills of our cheeseburger and milkshake-laden Western diet -- non-alcoholic fatty liver disease. The drug reversed liver inflammation, injury and scarring in animals fed a high fat, sugar and cholesterol diet. The diet was designed to replicate the Western fast food diet and recreate the features of non-alcoholic fatty liver disease found in people. The research team plans further testing to move it into human trials. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 3, 2017 Category: International Medicine & Public Health Source Type: news

Hepatitis B added to routine baby injections
First babies to be vaccinated in eight weeks to protect against liver diseases. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 31, 2017 Category: Consumer Health News Source Type: news

Liver disease and alcohol: How YOU could find out if you have symptomless disease
LIVER disease and cirrhosis - can increase the risk of cancer and can be caused by drinking too much alcohol. (Source: Daily Express - Health)
Source: Daily Express - Health - July 31, 2017 Category: Consumer Health News Source Type: news

Seeking Less-Invasive Care in Obesity-Related Liver Disease Seeking Less-Invasive Care in Obesity-Related Liver Disease
At DDW 2017, the focus was on finding better ways to detect disease and encourage weight loss. Dr William Balistreri highlights the results.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 28, 2017 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Hepatitis drugs more affordable but disease still deadly: WHO
GENEVA (Reuters) - Prices of drugs to cure hepatitis C and to treat hepatitis B are dropping dramatically, offering affordability and hope to 325 million people living with the viral liver disease that can be fatal, the World Health Organisation (WHO) said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - July 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Nigeria: World Hepatitis Day - Know Your Status to Avoid Liver Diseases, Minister Urges Nigerians
[Premium Times] Ahead of the World Hepatitis Day, Nigerians have been urged to know their hepatitis status towards preventing liver diseases and hepatitis-related deaths. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 27, 2017 Category: African Health Source Type: news

How to live longer: Three things you should do to add seven years to life
DRINKING alcohol should be drunk in moderation, experts warn, because overindulging can increase the risk of developing cancer, liver disease and even dementia. Scientists have revealed limiting alcohol content is one of the three things people can do to live longer. (Source: Daily Express - Health)
Source: Daily Express - Health - July 21, 2017 Category: Consumer Health News Source Type: news

FDA approves Vosevi for Hepatitis C
The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs - sofosbuvir and velpatasvir - and a new drug, voxilaprevir. (Source: World Pharma News)
Source: World Pharma News - July 19, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Can-Fite commences Phase II trial of namodenoson for NAFLD/NASH
Israeli biotechnology firm Can-Fite BioPharma is set to commence patient enrolment for a Phase II clinical trial of namodenoson to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), following the successful conc … (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for Hepatitis C
July 18, 2017 -- The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 18, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves Vosevi for Hepatitis C
The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 18, 2017 Category: American Health Source Type: news

Hepatitis C: New Drugs Cure It, But Most People Don ’t Know They Have It
Douglas T. Dieterich, MD Director, Institute of Liver Medicine Professor of Medicine, Division of Liver Disease Icahn School (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - July 17, 2017 Category: Consumer Health News Source Type: news

Obscure Asthma Drug Shows Promise for Treating Diabetes Obscure Asthma Drug Shows Promise for Treating Diabetes
A small proof-of-concept study has suggested that the asthma drug amlexanox could be repurposed to treat type 2 diabetes and may improve nonalcoholic fatty-liver disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news